Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › romosozumab

romosozumab

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of romosozumab

17 trials tracked of romosozumab: 5 in phase 3 or 4 and 4 with published results. The most-cited published study has 1442 citations.

17Trials tracked
5Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 5 Phase 2 5 Phase 1 7
  1. Phase 3 Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis Completed · 1,442 cited
  2. Phase 3 A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis Completed · 315 cited
  3. Phase 3 Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis Completed · 163 cited
  4. Phase 3 A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis Completed · 28 cited
  5. Phase 3 A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis Completed
  6. Phase 2 Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis Completed
Show 11 more trials
  1. Phase 2 Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing Completed
  2. Phase 2 Study To Assess FRacTure Healing With SclerosTin Antibody - Hip Completed
  3. Phase 2 Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density Completed
  4. Phase 2 Romosozumab in Women With Chronic SCI Completed
  5. Phase 1 Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta Completed
  6. Phase 1 A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785) Completed
  7. Phase 1 A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women Completed
  8. Phase 1 Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis Completed
  9. Phase 1 A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass Completed
  10. Phase 1 A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women Completed
  11. Phase 1 Transition From Alendronate to Romosozumab (AMG 785) Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Romosozumab improves shear bone strength in postmenopausal women with osteoporosis in BCT substudies
Drug Pipeline RCT
Romosozumab improves shear bone strength in postmenopausal women with osteoporosis in BCT substudies Romosozumab May Help Spinal Fusion Surgery Last Longer
This retrospective secondary analysis of phase 2 and 3 randomized trial data evaluated romosozumab in postmenopausal women with low bone den…
A bone drug may make spinal fusion surgery more secure for women with weak bones, new virtual tests suggest.
May 1, 2026
Narrative review examines coronary risk and vascular effects of bisphosphonates, denosumab, and romosozumab in osteoporosis
Diabetes & Endocrinology Sys. Review
Narrative review examines coronary risk and vascular effects of bisphosphonates, denosumab, and romosozumab in osteoporosis Osteoporosis drugs show no clear heart risk or benefit
This narrative review evaluates the cardiovascular safety profile of anti-osteoporosis therapies including bisphosphonates, denosumab, and r…
Common osteoporosis drugs don't have a clear effect on heart health, but one newer drug still raises safety questions.
Frontiers Apr 29, 2026